Skip to main content

Table 1 Distribution by country of nepafenac trial participants

From: Evaluating the re-identification risk of a clinical study report anonymized under EMA Policy 0070 and Health Canada Regulations

CountryNumber of subjects% of total subjects
United States50083.6
Panama264.3
Puerto Rico549
Other183
Total598100